About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

500mg Fulvestrant in HR+ MBC | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT03708432

500mg Fulvestrant in HR+ MBC

To study the real world use of 500mg Fulvestrant in HR+ MBC.

Lead sponsor: Fudan University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Fudan University

An observational, retrospective study of 500mg Fulvestrant in hormone receptor+/HER2- advanced breast cancer

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Diagnosed with ER/PR+，HER2- advanced breast cancer
•2. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
•3.500mg Fulvestrant treatment of advanced breast cancer for at least one month, between Jan 2011 and Dec 2015.
•4.Available medical history

Exclusion Criteria

•1. Incomplete medical history
•2. HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.

Related studies

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Advanced Breast Cancer

RECRUITINGPhase 4

A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients

NCT07578064 · Breast Cancer, Bone Marrow Suppression

RECRUITINGPhase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

RECRUITINGPhase 2

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998 · Breast Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 26, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment100

Start dateJul 2017

Last updatedFeb 26, 2024

Condition

Locations shown

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 26, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions